DIRS.INFO The most relevant business & tech news

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

☆ Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
▼ + stars: | 2023-05-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. "Valuation multiples across disease areas show CNS [ or central nervous system] and Genetic Medicine at relative low points." In July, the Food and Drug Administration could grant full approval to Leqembi , its Alzheimer's Disease treatment. As a very new area of medicine, gene therapy has greatest potential to accelerate sales growth as treatments come to market. He described immunology multiples as "generally stable" and genetic medicine multiples as highly volatile.

☆ Investors would be wise to heed these lessons from the 'retail apocalypse' as office values reset
▼ + stars: | 2023-05-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Still, it is also true that a lot of disruption occurred in between the events that prompted the "apocalypse" chatter and the firmer ground where retail real estate stands today. Recalling how these events played out is helpful in understanding the situation facing U.S. office properties. For office buildings, the pandemic knocked things out of whack. The same idea is being discussed for office buildings, but one-size will not fit all. There may be no surprise that there has been a huge drop-off in the number of loans with office properties as collateral since March.

☆ The CEO of this edtech company says A.I. can help unlock growth in the space. Here’s how
▼ + stars: | 2023-05-09 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

PWSC YTD mountain PowerSchool shares have fallen sharply since January, when they traded as high as $26.05. "For us, it's not a disruption from a negative perspective, it's actually phenomenal," he said, of the advancements in generative AI. Gulati expects generative AI will make it possible for PowerSchool to accelerate its goals to offer personalized learning plans. Still, PowerSchool shares are down 27% since the start of the year. Generative AI systems must be "trained" on data.

☆ Follow Warren Buffett's comments and all the action at Berkshire Hathaway's annual meeting: Live updates
▼ + stars: | 2023-05-06 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +1 min

Watch the 2023 Berkshire Hathaway annual shareholders meeting via CNBC's livestream in English or Mandarin or read about it here throughout the day. The CHI Health Center in Omaha, Nebraska, is welcoming tens of thousands for Berkshire Hathaway 's annual meeting on Saturday. The main event begins on Saturday when Chairman and CEO Warren Buffett and Vice Chairman Charlie Munger take the stage at 10:15 a.m. If previous gatherings are any guide, there will be a lively conversation about a wide range of topics. To prepare viewers for the main event, CNBC will begin its coverage at 9:45 a.m.

☆ Americans haven't been this worried about their bank deposits since the 2008 financial crisis
▼ + stars: | 2023-05-04 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +1 min

Recent events may be chipping away at confidence in the U.S. financial system, according to the findings of a Gallup survey. Nearly half of the 1,013 adults polled said they were "very worried" (19%) or "moderately worried" (29%) about the safety of the money they had tucked away in a bank or other financial institution, Gallup said. The level of concern expressed in the poll is similar to the findings that Gallup found shortly after the collapse of Lehman Brothers in September, 2008. Still, a December 2008 reading had shown sentiment had already improved from those worst levels as steps were taken to ease the impact of the financial crisis. When the poll was conducted from April 3-25 this year, Signature Bank and Silicon Valley Bank had already failed.

☆ Barclays downgrades a string of retail stocks as its hopes for a V-shaped recovery fade
▼ + stars: | 2023-05-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Consumers across all income levels are pulling back on spending, according to a Barclays Capital promotions tracker, prompting analyst Adrienne Yih to downgrade a host of retail stocks. However, Yih said, the pace of sales and discounting suggests that this scenario — a V-shaped recovery — is now less likely. FIGS 6M mountain Barclays downgraded Figs shares to underweight from equal weight. Figs shares shed 6%, Canada Goose fell more than 5% and Victoria's Secret was down more than 3%. CPRI YTD mountain Capri shares have fall 31% since the year started.

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

☆ The fallout from empty offices is coming. Here's where investors could see the pain
▼ + stars: | 2023-04-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +12 min

As concerns about regional banks roiled markets, investors weighed another threat: commercial real estate. Also, layered on top of the property value pressure, are the tightening credit conditions brought on by the recent turmoil in the banking sector. There is no doubt this scenario is a toxic mix for the capital-intensive real estate industry. At the moment, many experts say the real estate market isn't causing trouble for banks, but fears about the financial system are likely worsening conditions in real estate because liquidity is being reduced. The biggest concern is seeing how many other companies join Brookfield , Blackstone and Pimco in handing back the keys on office properties, Clancy said.

☆ Teens drive $67 billion in spending. Here's where they're putting their money, and why it's bad news for some stocks
▼ + stars: | 2023-04-07 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

The wide-ranging survey saw teenagers reporting their spending this year will rise 2% from the spring of 2022 to $2,419. Gen Z girls are planning to pull back on clothing spending, which could spell trouble for apparel stocks in the months ahead. It's the top choice of places to shop for about 9% of the upper-income teens in the survey, Piper said. According to the survey, 49% of upper-income teens have purchased clothes on secondhand marketplaces like Poshmark, The RealReal and ThredUp , or at local thrift stores. Nike remains entrenched as the top apparel brand among all teens, a position it's held for more than 12 years.

☆ Private equity firms Apollo and KKR among those reviewing Silicon Valley Bank loans
▼ + stars: | 2023-03-14 | by ( Seema Mody | ) www.cnbc.com time to read: +1 min

People wait outside the Silicon Valley Bank headquarters in Santa Clara, CA, to withdraw funds after the federal government intervened upon the bank's collapse, on March 13, 2023. Two of those people said Apollo may be interested in acquiring a piece of the business at par. Private equity firms Apollo Global Management and KKR are among the parties reviewing a book of loans held by Silicon Valley Bank, people familiar with the discussions told CNBC. Previously, Bloomberg reported that several private equity firms have been conducting due diligence on the loan assets. That report, which cited several people with knowledge of the talks, said Apollo, Ares Management , Blackstone , Carlyle Group and KKR were among those reviewing a potential deal.

☆ Under threat, Weight Watchers enters obesity drug space. Here's what it means for the stock
▼ + stars: | 2023-03-07 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

The company's sales have been in a steady multiyear decline after an attempt to de-emphasize weight loss and focus on wellness failed miserably. WW 1Y mountain The parent of Weight Watchers has seen its market value shrink as sales have dropped for several years. Another drug, Eli Lilly's Mounjaro, adds a second incretin hormone to the mix and has been shown to be even more successful with weight loss. This trend could provide an opportunity for the core Weight Watchers brand and its focus on behavior modification. That scenario assumes Weight Watchers continues to see membership erosion, while cost controls help minimize margin compression.

☆ This biotech startup has a chance to grab a piece of the lucrative obesity drug market, analysts say
▼ + stars: | 2023-02-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Enter biotech startup Structure Therapeutics , which is hoping to change that regimen with oral GLP-1 formulations for obesity and type 2 diabetes treatment. The stock rallied 73% in its first day of trading, but has pulled back in the weeks since its debut. Novo Nordisk's Wegovy and Ozempic are currently on the market and approved to treat obesity and type 2 diabetes. BMO was among the group of investment banks acting as joint book runners for Structure's IPO. (Jefferies was the lead book runner in Structure's IPO.)

☆ The pullback in this high-quality edtech stock could be opportunity for investors
▼ + stars: | 2023-02-24 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Knoblauch raised his price target to $27 from $21, saying the stock's underperformance so far this year is an opportunity. Last year, PowerSchool's stock outperformed its edtech peers by a wide margin. Demand for PowerSchool's products are largely driven by the growth of school budgets, which are recession-resilient. The international opportunity Thill said it's early days for PowerSchool's international expansion, and it's one of the reasons he's positive on the stock in the long term. We're particularly optimistic regarding the company's persona-based cloud bundles and international opportunity.

☆ Goldman sees another robust year for spinoffs. How to spot those that will outperform
▼ + stars: | 2023-02-21 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

In a research note published last week, Kostin updated that study to look at the track records of more recent spinoffs, completed over the past two years. "However, while 11 of the 20 spinoffs completed during 2022 outperformed the S & P 500 since transaction completion, only six of the spinoffs outperformed their parent entities." The largest completed deal in 2022 was General Electric' s spin off of GE HealthCare , a $26 billion business. The next largest completed deal last year was Intel's spinoff of Mobileye , which wrapped up on Oct. 26, 2022 . In 2021, the value of the completed spinoffs hit $112 billion, and included Dell's spinoff of VMWare , the largest deal at $57 billion.

☆ M.D. Sass is betting big on these out-of-favor stocks, expecting growth, recession or not
▼ + stars: | 2023-02-18 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

"Myself and the team really did a lot of introspection," Sass recalled, in an interview with CNBC. Sass Concentrated Value portfolio, which the younger Sass manages. By limiting the number of stocks, Sass said he can do extensive due diligence and research into each of the companies it owns. The goal is to find value in underappreciated companies that are in the midst of a transformation that will accelerate growth and ultimately lead to a boost in a stock's value. 'Digging under rocks' To place his bets, you won't see Sass looking strictly at a stock's price-to-earnings multiple.

☆ Why the Super Bowl still matters: Football is 'the glue' holding network TV together
▼ + stars: | 2023-02-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

And it came on top of a 9% bump in viewership during the 2021-22 football season, he said. Nathanson said the NFL is the biggest single driver of network ratings — and ultimately advertising dollars — during the fall TV season. "Sunday Night Football" is aired on NBC, while Disney, which owns ESPN and ABC, has the rights to show "Monday Night Football." Amazon has the rights to "Thursday Night Football" through 2033 . All this is to say, that there is a reason why advertisers still care about putting their commercials on during football games.

Bob Berg | Moment Mobile | Getty ImagesIn a fragmented media landscape, events like the Super Bowl are prized by advertisers for the exposure they offer. These commercials are an institution in and of themselves, with the ads generating conversation for weeks ahead and days after the big game. Consumers might recall well-crafted Super Bowl ads years after their debut. So does Super Bowl exposure truly help boost business? It drove so many viewers to Coinbase's app that it crashed on the night of the Super Bowl.

☆ Stocks making the biggest moves after hours: Disney, Mattel, Wynn Resorts, Affirm and more
▼ + stars: | 2023-02-08 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +3 min

Disney — Shares of the entertainment company rose more than 6% after the company released its fiscal first-quarter earnings report. Robinhood — Shares rose 5% after Robinhood missed revenue expectations in its latest earnings report. Analysts called for per-share earnings of $1.83 on revenue of $4.59 billion, according to FactSet. Although the company reported $1 billion in revenue for the latest quarter, compared to analysts' expectations of $958 million, according to Refinitiv. MGM beat analysts' estimates on fourth-quarter revenue, posting $3.59 billion compared to the $3.35 billion expected by Wall Street, according to Refinitiv.

☆ Nordstrom could use an activist, but Ryan Cohen might not be the right one
▼ + stars: | 2023-02-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Activist investor Ryan Cohen is building a stake in the department store chain as he looks to shake up its board, people familiar with the matter told CNBC. Tritton had once worked at Nordstrom, and Cohen thinks this makes him "conflicted and unqualified" to serve, the Journal report said. JWN 1D mountain Nordstrom shares surged after a report says Ryan Cohen is building a stake in the department store chain. 'Begs for an activist' The department store business hasn't been an easy one as shoppers buy more goods online or look to avoid large malls. The analyst also recalled that El Puerto de Liverpool, a Mexico City-based department store operator, holds a 10% stake in Nordstrom.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Stocks making the biggest moves after hours: Apple, Amazon, Ford and more
▼ + stars: | 2023-02-02 | by ( Jesse Pound | ) www.cnbc.com time to read: +5 min

Here are the notable stocks making moves after hours on Thursday, Feb. 2. Apple — The consumer tech stock tumbled 4% in extended trading after the company reported weaker-than-expected results for its fiscal first quarter. The company reported $1.88 in earnings per share on $117.15 billion of revenue. Amazon reported $149.20 billion in revenue for the quarter, above the $145.42 billion expected, according to Refinitiv. The company reported a 2% decline in comparable transactions year over year, thanks in part to weakness in China.

☆ In a water-scarce world, the Xylem-Evoqua deal makes sense. Why some think it's too expensive
▼ + stars: | 2023-01-23 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Evoqua shareholders will receive 0.480 Xylem shares, or about $52.89, for each one they own. That's a 29% premium to where Evoqua shares closed on Friday. Evoqua shares jumped 14% on the news, but Xylem shareholders are balking at what they see as a pricey deal. XYL 1Y mountain Xylem shares sell off in the wake of Evoqua deal That's one of problems Raymond James analyst Pavel Molchanov raised. Trading in Evoqua shares doesn't appear to indicate expectations of a competing bid surfacing, and some analysts have said they didn't expect one,.

☆ Here's where to look for the next developments in the fight against Alzheimer's disease
▼ + stars: | 2023-01-17 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +10 min

The Centers for Disease Control and Prevention estimates 5.8 million Americans were living with the disease in 2020 . BIIB 6M mountain Biogen's stock is trading well above its lows Leqembi treats Alzheimer's disease by targeting amyloid-beta plaques in the brain. Attention shifts to Eli Lilly Shares of other Alzheimer's drug developers have often mirrored Biogen's moves. Small drug developers Smaller Alzheimer's drug developers have also been boosted by research developments. Still in an early stage of its research, Prothena has traded as a proxy for developments in Alzheimer's treatment.

☆ A busier movie calendar will lead to a 15% jump in box office sales, JPMorgan predicts
▼ + stars: | 2023-01-15 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Slow and steady will win the race at the box office this year, according to JPMorgan analyst David Karnovsky. The first is tied to the depressed state of the box office last year . However, if additional movies are released, here's where there could be upside to his box office forecast. DIS 3M mountain Disney shares have gotten a boost from a proxy battle, but box office gains could be ahead. Paramount's "Top Gun: Maverick" topped the box office charts last year, while NBC Universal had new films in the Jurassic Park and Minions franchises.

Search resuls for: "Christina Cheddar"

25 mentions found